P393 Outcome of treat to target strategy in paediatric patients with Crohn’s disease and ulcerative colitis on infliximab
D. Yerlioglu*1, L. Cococcioni1, A. ElZein1, S. Sider1, S. Chadokufa1, R. Buckingham1, N. Shah1, A. Ocholi1, O. Borrelli1, F. Kiparissi1
1Great Ormond Street Hospital, Gastroenterology, London, UK
Treat to target strategy has been proposed in adult IBD to improve Quality of Life, symptoms and to treat inflammation. There are little data in the paediatric population for this approach. The aim of this study was to look if set goals (reduced PCDAI/PUCAI and Mayo/SES-CD) were achieved.
We conducted a retrospective analysis of children with IBD who received Infliximab (IFX) in our institution. Data were collected to evaluate mucosal healing for UC from colonoscopy results, using Mayo Scoring and for CD using SES-CD. We also compared These data with activity scores (PUCAI and PCDAI), CRP and Faecal Calprotectin, (FC).
A total of 61 patients were identified, 46 (Group 1) with Crohn’s disease (CD), 15 (Group 2) with ulcerative colitis (UC); Male
CRP pre-commencing median (
Our data suggest that set goals were achieved in CD with a decrease of SES-CD and in UC a decrease of the Mayo scoring with an improvement of PCDAI and PUCAI. We suggest that Paediatric patients get targets set at the beginning of their treatment and assess outcomes at set times.